Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.71%
1,092.80
-7.77
-0.71%
—1,100.571,098.941,103.801,084.24——
SIXC
Communications
SIXC
Communications
SIXC
-0.07%
604.74
-0.41
-0.07%
—605.15605.15606.69602.76——
SIXE
Energy
SIXE
Energy
SIXE
+1.64%
1,214.80
+19.61
+1.64%
—1,195.191,204.711,221.691,204.71——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,724.57
-15.34
-0.88%
—1,739.911,734.501,734.501,710.67——
SIXM
Financials
SIXM
Financials
SIXM
+0.14%
639.43
+0.87
+0.14%
—638.56640.21645.32638.69——
SIXR
Staples
SIXR
Staples
SIXR
+0.91%
839.15
+7.58
+0.91%
—831.57840.48844.16834.54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.06%
215.62
+2.26
+1.06%
—213.36213.36215.79212.77——
SIXT
Technology
SIXT
Technology
SIXT
-1.69%
3,179.52
-54.66
-1.69%
—3,234.183,171.863,195.363,145.46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.13%
936.91
+1.26
+0.13%
—935.65937.31941.44933.16——
SIXV
Health care
SIXV
Health care
SIXV
+0.24%
1,452.77
+3.51
+0.24%
—1,449.261,454.771,462.651,447.95——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,365.18
-17.27
-0.72%
—2,382.452,371.192,380.452,362.86——
TRVN:OTCMKTS
Trevena Inc
$0.011
0.00%
(0.00) 1D
Apr 28, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRVN...
Open
$0.01
High
$0.01
Low
$0.01
Mkt. cap
10.64K
Avg. vol.
157.00
Volume
215.00
52-wk high
$1.28
52-wk low
$0.00
Beta
0.68
Shares outstanding
864.00K
No. of employees
23
News stories
From sources across the web
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees23
Founded2007
HeadquartersAtlanta, Georgia, United States
SectorBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Revenue
-82.00K
20.00K
325.00K
283.00K
Cost of goods sold
-
88.00K
103.00K
114.00K
Cost of revenue
-
88.00K
103.00K
114.00K
Research and development expenses
-
3.96M
3.13M
1.87M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
5.84M
3.60M
3.88M
Operating expense
-
9.81M
6.72M
5.75M
Total operating expenses
-
9.90M
6.83M
5.86M
Operating income
-
-9.88M
-6.50M
-5.58M
Other non operating income
-
2.36M
1.92M
479.00K
EBT including unusual items
-
-7.68M
-4.86M
-4.91M
EBT excluding unusual items
-
-7.68M
-4.86M
-4.91M
Income tax expense
-
-
31.00K
30.00K
Effective tax rate
-
-
-0.64%
-0.61%
Other operating expenses
-
-
-
-
Net income
-
-7.68M
-4.89M
-4.94M
Net profit margin
-
-38,390.00%
-1,504.92%
-1,745.23%
Earnings per share
-
-
-
-
Interest and investment income
-
353.00K
238.00K
190.00K
Interest expense
-
-513.00K
-521.00K
-1.00K
Net interest expenses
-
-160.00K
-283.00K
189.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-9.79M
-6.41M
-5.48M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more